Eli Lilly (LLY) and Company announced an additional $4.5B investment across two of its three Lebanon sites-bringing the company’s total Indiana capital expansion commitments since 2020 to more than $21B. Lilly’s evolving pipeline, as well as anticipated demand for its medicines, prompted this additional commitment. The investment will incorporate new process designs and technologies at Lilly Lebanon API, one of the company’s future active pharmaceutical ingredient sites, as well as Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility opening today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Earnings: NVO Stock Rises as Wegovy Sales Drive Massive Q1 Beat
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- Trump Trade: Microsoft, Google agree to U.S. security reviews of AI models
- Eli Lilly announces new long-term Omvoh data
- Eli Lilly price target raised to $1,400 from $1,350 at Barclays